Beyond Adderall: Non-Stimulant ADHD Medication Options.
For most people with ADHD, stimulant medications like Adderall, Vyvanse, or Ritalin are the first thing a doctor reaches for, and for good reason: they're the most effective option we have, backed by decades of research. But they aren't the right fit for everyone.
Maybe stimulants left you feeling wired, anxious, or flat. Maybe they disrupted your sleep or appetite, or nudged your heart rate and blood pressure in a direction your doctor didn't love. Maybe you'd rather not take a controlled substance, or you have a personal or family history that makes one a poor choice. Whatever the reason, there's a whole category of ADHD medication that works differently — and for a lot of people, works well.
What makes a medication "non-stimulant"
Non-stimulant ADHD medications don't act on the brain the fast, direct way stimulants do. A few practical differences follow from that:
They aren't controlled substances, so there's a lower risk of misuse and no monthly-prescription hassle. They're taken every day and need to build up gradually, so they can take a few weeks to reach full effect rather than working within an hour. And once they're working, they tend to provide steady, around-the-clock coverage instead of wearing off in the afternoon.
They're often a good choice when stimulants cause intolerable side effects, when there's anxiety or another condition in the mix, when a controlled substance isn't appropriate, or as an add-on to a stimulant to smooth out coverage. Their effect sizes are generally smaller than stimulants', which is why stimulants usually come first — but for the right person, a non-stimulant can be the difference between white-knuckling the day and actually functioning (Cortese et al., Lancet Psychiatry, 2018).
The established non-stimulant options
Atomoxetine (Strattera). The best-known non-stimulant, atomoxetine is a selective norepinephrine reuptake inhibitor. It's FDA-approved for children and adults, isn't a controlled substance, and provides 24-hour coverage. It can take four to six weeks to reach full effect, so patience is part of the deal. It's often a strong candidate when anxiety travels alongside ADHD.
Viloxazine (Qelbree). A newer norepinephrine reuptake inhibitor approved for both children and adults. Like atomoxetine, it's non-controlled and taken daily, and it gives some prescribers another lever to pull when the first non-stimulant isn't quite right.
Guanfacine (Intuniv). Originally a blood-pressure medication, guanfacine is an alpha-2 agonist that can improve focus, impulsivity, and hyperactivity. It's frequently used on its own or added to a stimulant to extend coverage or take the edge off. Because it can lower blood pressure and cause some drowsiness, dosing is adjusted gradually.
Clonidine (Kapvay). Another alpha-2 agonist, clonidine tends to be more sedating than guanfacine, which can be a downside during the day but a genuine advantage for people whose ADHD comes with significant sleep trouble or nighttime restlessness.
Bupropion (Wellbutrin), off-label. Not FDA-approved for ADHD, but sometimes used off-label — especially when depression is also part of the picture. Whether it fits is a conversation for you and your prescriber.
A note on Simtriyo (centanafadine) — the newest option
If you've seen buzz about a brand-new ADHD drug called Simtriyo, here's an honest read, because the coverage has been misleading.
Simtriyo (centanafadine) was approved by the FDA in July 2026. It's genuinely novel — the first medication of its kind, a norepinephrine-dopamine-serotonin reuptake inhibitor, meaning it acts on all three of those brain chemicals at once. It was developed and widely discussed for years as a non-stimulant, and a lot of headlines still describe it that way.
But that's not how it was approved. The final FDA label classifies Simtriyo as a central nervous system stimulant, and it carries a boxed warning for abuse, misuse, and addiction. In other words, despite the expectations, it landed as a controlled stimulant — not a non-stimulant alternative.
Two practical things to know if you're curious about it:
It isn't available yet. Because it's classified as a stimulant, the DEA has to assign it a controlled-substance schedule before any pharmacy can fill it. That process was still underway as of this writing, with availability expected later in 2026.
Its benefit appears modest. In its trials, Simtriyo reduced ADHD symptoms compared with placebo, but the size of that effect sits toward the lower end of the range — closer to the non-stimulants than to a strong stimulant. Its distinct mechanism may still make it a worthwhile option for people who haven't found a good fit elsewhere, particularly given its once-daily dosing.
The honest bottom line: Simtriyo is an interesting new tool, not a non-stimulant, and not yet something you can pick up at the pharmacy. If it becomes available and you're wondering whether it fits, that's a conversation worth having with a prescriber who has read the label closely.
Finding the right fit in Austin
There's rarely one obviously "correct" ADHD medication. Finding the right one is a process of matching the medication to your biology, your other health conditions, your daily rhythm, and your preferences — and adjusting as you learn how you respond. Non-stimulants widen that toolkit considerably, especially for people for whom stimulants aren't a clean fit.
If stimulants haven't worked for you, or you'd rather explore other paths, our team in Austin can help you weigh the options and build a plan that fits your life. You can learn more about how we approach ADHD and our clinicians.
Ready to take the next step?
Estela Mental Health is located in Austin and accepts several major insurance plans including Aetna, Blue Cross Blue Shield, Cigna/Evernorth, Optum, and United Healthcare.
Book an appointment today — and let's find what works for you.Related: ADHD · Anxiety · Our Clinicians · Appointments
Sources
Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
Simtriyo (centanafadine) US Prescribing Information. Otsuka Pharmaceutical; approved July 2026.
